At the end of 2019, Rigvir Group successfully attracted investments of EUR 500,000. Investments are attracted from an investor syndicate, including Pharma VC, a company managed by well-known and respectable venture capital investors in Northern Europe. The investment will be used in accordance with the Rigvir science program to strengthen the product's scientific capacity.